918431-93-3 Usage
Description
1-Piperidinecarboxylic acid, 4-cyano-4-fluoro-, 1,1-dimethylethyl ester, also known as Tavapadon, is a chemical compound with the molecular formula C13H18N2O2F. It is being developed as a potential treatment for Parkinson's disease, targeting dopamine receptors in the brain to regulate dopamine levels, which are crucial for controlling movement and coordination. The 1,1-dimethylethyl ester form enhances its stability and bioavailability, making it more effective for therapeutic use.
Uses
Used in Pharmaceutical Industry:
1-Piperidinecarboxylic acid, 4-cyano-4-fluoro-, 1,1-dimethylethyl ester is used as a potential treatment for Parkinson's disease for its ability to target dopamine receptors in the brain and regulate dopamine levels, which are essential for controlling movement and coordination. Its 1,1-dimethylethyl ester form improves its stability and bioavailability, making it a promising candidate for therapeutic use in this industry. Currently, it is undergoing clinical trials to evaluate its safety and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 918431-93-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,8,4,3 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 918431-93:
(8*9)+(7*1)+(6*8)+(5*4)+(4*3)+(3*1)+(2*9)+(1*3)=183
183 % 10 = 3
So 918431-93-3 is a valid CAS Registry Number.
918431-93-3Relevant articles and documents
KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 0413; 0415, (2016/09/26)
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
Design, synthesis, and evaluation of a novel 4-aminomethyl-4- fluoropiperidine as a T-type Ca2+ channel antagonist
Shipe, William D.,Barrow, James C.,Yang, Zhi-Qiang,Lindsley, Craig W.,Yang, F. Vivien,Schlegel, Kelly-Ann S.,Shu, Youheng,Rittle, Kenneth E.,Bock, Mark G.,Hartman, George D.,Tang, Cuyue,Ballard, Jeanine E.,Kuo, Yuhsin,Adarayan, Emily D.,Prueksaritanont, Thomayant,Zrada, Matthew M.,Uebele, Victor N.,Nuss, Cindy E.,Connolly, Thomas M.,Doran, Scott M.,Fox, Steven V.,Kraus, Richard L.,Marino, Michael J.,Graufelds, Valerie Kuzmick,Vargas, Hugo M.,Bunting, Patricia B.,Hasbun-Manning, Martha,Evans, Rose M.,Koblan, Kenneth S.,Renger, John J.
supporting information; scheme or table, p. 3692 - 3695 (2009/04/07)
The novel T-type antagonist (S)-5 has been prepared and evaluated in in vitro and in vivo assays for T-type calcium ion channel activity. Structural modification of the piperidine leads 1 and 2 afforded the fluorinated piperidine (S)-5, a potent and selec
